TGTX continues to perform with Briumvi IV, and clinical readouts provide the opportunity to go well beyond current sales.

The Financial Reporting Council (FRC) has issued a couple of updates that will affect some preparers and auditors.

Zhihu has struggled after the stock started 2026 with a major rally, which seems to have been caused by a combination of factors. Learn why ZH stock is a buy.

Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS(TM) (zopapogene imadenovec-drba), the first-and-only FDA-approved treatment for adults with RRP, in August 2025 -- ...

DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced its financial results for the fourth quarter and full-year 2025, along ...

Considerations in accounting for income taxes can include choice of method and classification of assets and liabilities.

Full Year 2025 Revenue of $12.2 Million, up 169% from 2024 Revenue of $2.8 Million for Q4 2025, up 116% from Q4 2024Gross Profit of $2.3 Million ...

Company enters 2026 with reduced leverage, extended debt maturity and added liquidity Pursues top-line stabilization and margin expansion with ...

Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Investopedia / Candra Huff Other ...

GOOD FINANCIAL PERFORMANCE IN 2025 (ADJUSTED HEADLINE PBIT UP 6.5% TO €8.04 M AND ADJUSTED EPS UP BY 20.8% TO €0.33); ...

Virgin Galactic Holdings, Inc. (NYSE: SPCE) (“Virgin Galactic” or the “Company”) today announced its financial results for the fourth quarter and full year ended December 31, 2025 and provided a ...

I am writing to you for the first time as CEO of Bakkt. When I joined the company, it was clear that significant rebuilding was required. Bakkt possessed something rare - a deep regulatory foundation ...